Nektar Therapeutics (NKTR) Net Margin (2010 - 2026)
Nektar Therapeutics' (NKTR) quarterly Net Margin came in at 397.33% in Q1 2026, up 4647.0% year-on-year from 8.37% in Q1 2025, and down 22347.08% quarter-over-quarter from 1.77% in Q4 2025.
Nektar Therapeutics (NKTR) Net Margin (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Net Margin history runs 17 years deep, the most recent figure standing at 397.33% for Q1 2026.
- On a quarterly basis, Net Margin rose 4647.0% year-over-year to 397.33% in Q1 2026; TTM through Mar 2026 was 211.63%, a 9267.0% decrease from a year earlier, with the FY2025 full-year figure at 219.08%, down 12341.0% from the prior year.
- Net Margin eased to 397.33% in Q1 2026 per NKTR's latest filing, from 1.77% in the prior quarter.
- Across five years, Net Margin topped out at 109.87% in Q4 2024 and bottomed at 736.94% in Q2 2022.
- The 5-year median for Net Margin is 249.39% (2023), against an average of 260.98%.
- Across the five-year window, Net Margin plunged 142303 bps in 2022 and surged 48755 bps in 2023, its largest moves.
- Year by year, Net Margin stood at 91.6% in 2022, then sank by 292 bps to 176.17% in 2023, then soared by 162 bps to 109.87% in 2024, then slumped by 102 bps to 1.77% in 2025, then plunged by 22347 bps to 397.33% in 2026.
- Per Business Quant, the three latest NKTR Net Margin figures stand at 397.33% (Q1 2026), 1.77% (Q4 2025), and 296.76% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Nektar Therapeutics | 2.04 Bn | 1.48 Bn | 3.16 Mn | -397.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -397.33% |
| Dec 31, 2025 | -1.77% |
| Sep 30, 2025 | -296.76% |
| Jun 30, 2025 | -350.85% |
| Mar 31, 2025 | -443.80% |
| Dec 31, 2024 | 109.87% |
| Sep 30, 2024 | -153.61% |
| Jun 30, 2024 | -222.93% |
| Mar 31, 2024 | -170.07% |
| Dec 31, 2023 | -176.17% |
| Sep 30, 2023 | -189.85% |
| Jun 30, 2023 | -249.39% |
| Mar 31, 2023 | -634.52% |
| Dec 31, 2022 | 91.60% |
| Sep 30, 2022 | -249.94% |
| Jun 30, 2022 | -736.94% |
| Mar 31, 2022 | -364.16% |
| Dec 31, 2021 | 1,514.63% |
| Sep 30, 2021 | -520.47% |
| Jun 30, 2021 | -443.06% |